Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionSH3 domain binding

SYNJ2 DENND1A MAP4K3 CD2AP

3.34e-05143264GO:0017124
DomainNUT

NUTM2F NUTM2G

1.72e-055252IPR024310
DomainNUT_N

NUTM2F NUTM2G

1.72e-055252IPR024309
DomainNUT

NUTM2F NUTM2G

1.72e-055252PF12881
DomainSH3_2

MYO15B BAIAP2 CD2AP

2.01e-0486253IPR011511
DomainSH3_2

MYO15B BAIAP2 CD2AP

2.01e-0486253PF07653
DomainSH3

MYO15B BAIAP2 CD2AP

2.91e-03216253PS50002
DomainSH3

MYO15B BAIAP2 CD2AP

2.91e-03216253SM00326
DomainSH3_domain

MYO15B BAIAP2 CD2AP

3.06e-03220253IPR001452
DomainSH3_9

BAIAP2 CD2AP

4.85e-0378252PF14604
Domain-

MLXIPL ATOH8

9.28e-031092524.10.280.10
DomainHLH

MLXIPL ATOH8

9.60e-03111252PF00010
DomainHLH

MLXIPL ATOH8

1.05e-02116252SM00353
DomainBHLH

MLXIPL ATOH8

1.06e-02117252PS50888
DomainbHLH_dom

MLXIPL ATOH8

1.08e-02118252IPR011598
PathwayREACTOME_RHO_GTPASES_ACTIVATE_WASPS_AND_WAVES

BAIAP2 WIPF2

4.86e-0436132M27549
PathwayREACTOME_RHO_GTPASE_CYCLE

BAIAP2 DBT WIPF2 RHOBTB2

5.82e-04450134M27078
Pubmed

Nuclear actin interactome analysis links actin to KAT14 histone acetyl transferase and mRNA splicing.

BAIAP2 KMT2B RAPH1 WIPF2 SF3A1 SCAF4

1.66e-0650626630890647
Pubmed

ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome.

ZHX2 CD2AP

5.37e-06526217056598
Pubmed

Interaction network of human early embryonic transcription factors.

ERF KMT2B DBT ZHX2 SOBP

5.62e-0635126538297188
Pubmed

Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.

BAIAP2 WIPF2 SF3A1 SCAF4

2.09e-0522026424550385
Pubmed

The human cytoplasmic dynein interactome reveals novel activators of motility.

BAIAP2 DBT RAPH1 SYNJ2 MAP4K3 CD2AP

3.24e-0585326628718761
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

MLXIPL BAIAP2 RAPH1 SYNJ2 DENND1A CD2AP

3.41e-0586126636931259
Pubmed

Missing-in-metastasis MIM/MTSS1 promotes actin assembly at intercellular junctions and is required for integrity of kidney epithelia.

BAIAP2 CD2AP

4.17e-051326221406566
Pubmed

A census of human transcription factors: function, expression and evolution.

ZFHX2 SP2 MLXIPL ERF ZHX2 ATOH8

4.58e-0590826619274049
Pubmed

E-cadherin interactome complexity and robustness resolved by quantitative proteomics.

BAIAP2 RAPH1 SYNJ2 WIPF2 CD2AP

5.51e-0556526525468996
Pubmed

Prediction of the coding sequences of unidentified human genes. XIX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

ZFHX2 RAPH1 SPEF2

6.06e-0510226311214970
Pubmed

Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor.

WIPF2 MAP4K3 CD2AP

6.24e-0510326321706016
Pubmed

Human transcription factor protein interaction networks.

SP2 ERF KMT2B DBT ZHX2 SOBP SCAF4

6.44e-05142926735140242
Pubmed

Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS.

RAPH1 SYNJ2 WIPF2

7.19e-0510826319531213
Pubmed

Tuba, a novel protein containing bin/amphiphysin/Rvs and Dbl homology domains, links dynamin to regulation of the actin cytoskeleton.

RAPH1 WIPF2

7.26e-051726214506234
Pubmed

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

ZFHX2 BAIAP2 ZHX2 SYNJ2 DENND1A SOBP CD2AP

8.34e-05148926728611215
Pubmed

Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.

KMT2B SYNJ2 MAP4K3 CD2AP

9.97e-0532926417474147
Pubmed

WW domains provide a platform for the assembly of multiprotein networks.

WIPF2 SF3A1 SCAF4

2.05e-0415426316055720
Pubmed

Identification and functional characterization of transcriptional activators in human cells.

SP2 ERF NUTM2F ZHX2

2.07e-0439826435016035
Pubmed

Wnt regulation: exploring Axin-Disheveled interactions and defining mechanisms by which the SCF E3 ubiquitin ligase is recruited to the destruction complex.

MLXIPL BAIAP2 DBT SF3A1 CD2AP

2.95e-0480926532129710
Pubmed

H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.

SP2 MLXIPL ERF KMT2B SF3A1 SCAF4

3.18e-04129426630804502
Pubmed

A germline-specific class of small RNAs binds mammalian Piwi proteins.

KMT2B WIPF2 SF3A1 RHOBTB2

3.30e-0445026416751776
Pubmed

A human MAP kinase interactome.

BAIAP2 SYNJ2 WIPF2 MAP4K3

4.41e-0448626420936779
Pubmed

BioID Performed on Golgi Enriched Fractions Identify C10orf76 as a GBF1 Binding Protein Essential for Golgi Maintenance and Secretion.

DBT RAPH1 CD2AP

5.53e-0421626331519766
Pubmed

The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.

BAIAP2 KMT2B ZHX2 DENND1A CD2AP SCAF4

6.90e-04149726631527615
Pubmed

SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.

KMT2B RAPH1 CD2AP SCAF4

6.97e-0454926438280479
InteractionACTC1 interactions

BAIAP2 KMT2B NUTM2F RAPH1 WIPF2 SF3A1 CD2AP SCAF4

1.71e-06694268int:ACTC1
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZFHX2 ZHX2

6.70e-0515152529
GeneFamilyBasic helix-loop-helix proteins

MLXIPL ATOH8

3.66e-03110152420
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZFHX2 SP2 ZHX2

1.99e-0271815328
CoexpressionGSE39110_DAY3_VS_DAY6_POST_IMMUNIZATION_CD8_TCELL_WITH_IL2_TREATMENT_DN

ZHX2 MAP4K3 RHOBTB2 CD2AP

3.60e-05199254M9283
CoexpressionGSE17721_PAM3CSK4_VS_GADIQUIMOD_24H_BMDC_DN

ANTXR2 DBT MAP4K3 CD2AP

3.67e-05200254M3981
ToppCell343B-Myeloid-Macrophage-FABP4+_Macrophage|Macrophage / Donor, Lineage, Cell class and subclass (all cells)

MYO15B C10orf55 SYNJ2

4.83e-05122263a2f343962069253a08faa80fd70723b8488a99ec
ToppCellTCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Tubular-6|TCGA-Stomach / Sample_Type by Project: Shred V9

RAPH1 WIPF2 CD2AP

1.06e-04159263655c0749c238bd68cb797adb83e25a23b8a3cc9d
ToppCellBAL-Severe-Lymphocyte-B-B_cell|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ANTXR2 SOBP RHOBTB2

1.53e-04180263c3c72531af5b9f7a7416727fe609dab5180e03b6
ToppCellBAL-Severe-Lymphocyte-B-B_cell-B_cell|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ANTXR2 SOBP RHOBTB2

1.53e-04180263b465f2f8b0e9a2034a4f1272bb00c77439164dbf
ToppCellBAL-Severe-Lymphocyte-B-B_cell-B_cell-B_activate-7|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ANTXR2 SOBP RHOBTB2

1.53e-041802639f4bbaf6435c23e3e552ae22be8ea7884314192d
ToppCell356C-Lymphocytic-CD4_T-cell-Treg_cell_2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

DENND1A MAP4K3 SF3A1

1.61e-04183263f142b320023eef00b48d4820c46214c9794d37e7
ToppCellLPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

BAIAP2 ATOH8 CD2AP

1.63e-0418426342ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell356C-Lymphocytic-CD4_T-cell-Treg_cell_2|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)

DENND1A MAP4K3 SF3A1

1.66e-04185263e06a784a297f357f3f8e761c24fa70722048ab42
ToppCellnormal_Lung-Myeloid_cells-pDCs|Myeloid_cells / Location, Cell class and cell subclass

MYO15B ANTXR2 CD2AP

1.71e-04187263a3592f056e1c2f82ba325fea2ecc4dd6c6347c81
ToppCellnormal_Lung-Myeloid_cells-pDCs|normal_Lung / Location, Cell class and cell subclass

MYO15B ANTXR2 CD2AP

1.71e-04187263d36751372fd40a46441f07735c9c3c5dcb503f24
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

RAPH1 MAP4K3 CD2AP

1.85e-041922632510f22197502f60fd266b7f42eff040f25b8ae7
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

RAPH1 MAP4K3 CD2AP

1.85e-04192263e8e316f396834bcd34843e56e1d86f310fd6aada
ToppCell10x_3'_v2v3-Non-neoplastic-Vascular-Mural_cell-Pericyte-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ERF DENND1A SCAF4

1.85e-041922630b954a4e5857dac45d97c491af9b27cb2d1bd339
ToppCellnucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ZHX2 DENND1A MAP4K3

1.88e-04193263779276e775cb2492e8dd36436295a536084a6415
ToppCellPBMC-Mild|PBMC / Compartment, Disease Groups and Clusters

BAIAP2 MAP4K3 CD2AP

1.91e-04194263d1366b169d14011194e61d16b6b0953349febc78
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

RAPH1 MAP4K3 CD2AP

1.91e-04194263abacb6a8d7a9003f2f6c2be0305507f1c1c50347
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

RAPH1 MAP4K3 CD2AP

1.91e-0419426346070fbb0ee0eb9e1801c43b73a15707471056dc
ToppCellTracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations

ZHX2 DENND1A MAP4K3

2.06e-0419926394b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCellLPS_only-Epithelial_alveolar-AT_1|LPS_only / Treatment groups by lineage, cell group, cell type

BAIAP2 ATOH8 CD2AP

2.09e-042002639a6ae40f3e17cd44ee5fd73260713b920aa2ea15
ToppCellLPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type

BAIAP2 ATOH8 CD2AP

2.09e-042002632dadf317a42a7e27cc1fac74f91b806c93a57108
Drug(cis-) Nanophine [5072-45-7]; Down 200; 26.8uM; PC3; HT_HG-U133A

BAIAP2 ZHX2 SOBP RHOBTB2 SCAF4

2.75e-061992654543_DN
DrugIS-50

ANTXR2 CD2AP

5.61e-0510262CID000493342
DrugMIBC

MLXIPL CD2AP

6.85e-0511262CID000007910
DrugBaclofen (R,S) [1134-47-0]; Up 200; 18.8uM; MCF7; HT_HG-U133A

ZFHX2 BAIAP2 SYNJ2 SCAF4

6.86e-051962641536_UP
DrugMefenamic acid [61-68-7]; Up 200; 16.6uM; PC3; HT_HG-U133A

KMT2B DBT SYNJ2 SCAF4

6.86e-051962641821_UP
DrugDO 897/99; Up 200; 8.2uM; HL60; HG-U133A

KMT2B DBT ZHX2 SCAF4

6.86e-051962641728_UP
DrugHydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; PC3; HT_HG-U133A

ERF KMT2B DBT SCAF4

6.86e-051962642119_DN
DrugPilocarpine nitrate [148-72-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A

ERF KMT2B DBT SYNJ2

7.00e-051972645341_DN
DrugParoxetine maleate [64006-44-6]; Down 200; 1uM; PC3; HT_HG-U133A

BAIAP2 ERF KMT2B ZHX2

7.00e-051972644556_DN
DrugLobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; MCF7; HT_HG-U133A

BAIAP2 KMT2B SYNJ2 CD2AP

7.00e-051972642763_DN
DrugSulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A

BAIAP2 ERF DBT SOBP

7.00e-051972645098_DN
DrugSparteine (-) [90-39-1]; Down 200; 17uM; PC3; HT_HG-U133A

BAIAP2 KMT2B SYNJ2 RHOBTB2

7.14e-051982644568_DN
DrugBacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; PC3; HT_HG-U133A

KMT2B SYNJ2 RHOBTB2 SCAF4

7.14e-051982644592_DN
DrugTrapidil [15421-84-8]; Down 200; 19.4uM; MCF7; HT_HG-U133A

ZFHX2 BAIAP2 DBT WIPF2

7.14e-051982646515_DN
DrugHomatropine hydrobromide (R,S) [51-56-9]; Up 200; 11.2uM; PC3; HT_HG-U133A

ZFHX2 KMT2B DBT SYNJ2

7.14e-051982641806_UP
DrugZoxazolamine [61-80-3]; Down 200; 23.8uM; MCF7; HT_HG-U133A

BAIAP2 DBT SYNJ2 SCAF4

7.14e-051982642625_DN
DrugThioridazine hydrochloride [130-61-0]; Down 200; 9.8uM; PC3; HT_HG-U133A

ERF DBT RHOBTB2 SCAF4

7.28e-051992644085_DN
DrugCyclopentolate hydrochloride [5870-29-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A

SP2 BAIAP2 SF3A1 SCAF4

7.28e-051992646214_DN
DrugBromopride [4093-35-0]; Down 200; 11.6uM; PC3; HT_HG-U133A

ERF KMT2B SYNJ2 RHOBTB2

7.28e-051992644278_DN
DrugPF-00562151-00 [351320-12-2]; Down 200; 10uM; PC3; HT_HG-U133A

BAIAP2 KMT2B SYNJ2 SCAF4

7.42e-052002646907_DN
Drugcarbyne

SP2 CD2AP

1.49e-0416262CID000007551
Drugetheno-NAD

BAIAP2 RAPH1 WIPF2

2.23e-04104263CID005288160
Drugbutenolide

SP2 CD2AP

3.70e-0425262CID000010341
DrugAC1L1BQO

DBT SOBP

5.00e-0429262CID000001562
DrugFMNH2

SP2 DBT

6.88e-0434262CID000000711
Drugnojirimycin

SP2 ERF

8.60e-0438262CID000065242
Drugtrichostatin A; Down 200; 0.1uM; MCF7; HG-U133A

BAIAP2 ZHX2 SYNJ2

1.09e-03179263332_DN
DrugEllipticine [519-23-3]; Up 200; 16.2uM; HL60; HG-U133A

ERF DENND1A CD2AP

1.18e-031842631765_UP
Drug0179445-0000 [211246-22-9]; Down 200; 10uM; MCF7; HT_HG-U133A

ZHX2 SYNJ2 SOBP

1.20e-031852634755_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

KMT2B SYNJ2 SOBP

1.21e-03186263831_DN
DrugSulfaphenazole [526-08-9]; Up 200; 12.8uM; PC3; HT_HG-U133A

KMT2B SOBP RHOBTB2

1.23e-031872631794_UP
DrugEthynodiol diacetate [297-76-7]; Down 200; 10.4uM; HL60; HT_HG-U133A

ZHX2 SYNJ2 RHOBTB2

1.25e-031882633102_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

ERF SYNJ2 WIPF2

1.29e-031902631056_DN
DrugButylparaben [94-26-8]; Down 200; 20.6uM; PC3; HT_HG-U133A

ERF DBT SYNJ2

1.31e-031912634647_DN
DrugTriflupromazine hydrochloride [1098-60-8]; Up 200; 10.2uM; PC3; HT_HG-U133A

KMT2B SOBP SCAF4

1.31e-031912631813_UP
DrugProchlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; PC3; HT_HG-U133A

KMT2B DBT SYNJ2

1.33e-031922636664_DN
DrugCarcinine [56897-53-1]; Down 200; 22uM; MCF7; HT_HG-U133A

BAIAP2 SYNJ2 SCAF4

1.35e-031932633242_DN
DrugClotrimazole [23593-75-1]; Down 200; 11.6uM; PC3; HT_HG-U133A

BAIAP2 SYNJ2 RHOBTB2

1.35e-031932635726_DN
Drug0175029-0000 [211245-78-2]; Up 200; 10uM; MCF7; HT_HG-U133A

DBT SYNJ2 DENND1A

1.35e-031932634713_UP
DrugTrichlorfon [52-68-6]; Down 200; 15.6uM; MCF7; HT_HG-U133A

BAIAP2 DBT SYNJ2

1.35e-031932635989_DN
DrugDiphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; PC3; HT_HG-U133A

ZFHX2 KMT2B DBT

1.35e-031932631830_UP
Drugtroglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

ZFHX2 BAIAP2 SCAF4

1.35e-031932631657_UP
DrugKetanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; MCF7; HT_HG-U133A

BAIAP2 DBT SCAF4

1.35e-031932633209_DN
DrugHycanthone [3105-97-3]; Down 200; 11.2uM; PC3; HT_HG-U133A

DBT SYNJ2 SOBP

1.35e-031932634630_DN
Drugcarbamazepine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

SP2 BAIAP2 SOBP

1.35e-03193263835_DN
DrugMetoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; PC3; HT_HG-U133A

BAIAP2 ZHX2 RHOBTB2

1.35e-031932634285_DN
DrugAcetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A

KMT2B SYNJ2 SCAF4

1.37e-031942635384_DN
DrugEpivincamine [6835-99-0]; Up 200; 11.2uM; HL60; HG-U133A

BAIAP2 WIPF2 SCAF4

1.37e-031942631783_UP
DrugPridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

BAIAP2 KMT2B DBT

1.37e-031942637214_DN
DrugAlbendazole [54965-21-8]; Up 200; 15uM; MCF7; HT_HG-U133A

BAIAP2 KMT2B SYNJ2

1.37e-031942637164_UP
DrugHexestrol [84-16-2]; Down 200; 14.8uM; HL60; HT_HG-U133A

DBT WIPF2 MAP4K3

1.37e-031942632515_DN
DrugMemantine Hydrochloride [41100-52-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A

DBT SYNJ2 SF3A1

1.37e-031942637354_DN
DrugAndrosterone [53-41-8]; Down 200; 13.8uM; MCF7; HT_HG-U133A

BAIAP2 DBT SCAF4

1.37e-031942635696_DN
DrugBuflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A

BAIAP2 SYNJ2 SCAF4

1.37e-031942633274_DN
DrugMoxalactam disodium salt [64953-12-4]; Down 200; 7uM; PC3; HT_HG-U133A

BAIAP2 KMT2B RHOBTB2

1.37e-031942634648_DN
Drugwortmannin; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA

BAIAP2 KMT2B RHOBTB2

1.39e-03195263911_DN
DrugMinaprine dihydrochloride [25953-17-7]; Down 200; 10.8uM; HL60; HG-U133A

SP2 DBT DENND1A

1.39e-031952631968_DN
DrugMifepristone [84371-65-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A

BAIAP2 DBT SCAF4

1.39e-031952633185_DN
DrugFursultiamine Hydrochloride [2105-43-3]; Down 200; 9.2uM; HL60; HT_HG-U133A

KMT2B DBT WIPF2

1.39e-031952632929_DN
DrugBumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A

KMT2B SYNJ2 RHOBTB2

1.39e-031952635117_DN
Drugradicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A

ERF KMT2B SYNJ2

1.39e-031952636938_DN
DrugApramycin [37321-09-8]; Down 200; 7.4uM; PC3; HT_HG-U133A

BAIAP2 SYNJ2 SOBP

1.39e-031952636614_DN
DrugPentamidine isethionate [140-64-7]; Down 200; 6.8uM; MCF7; HT_HG-U133A

ZFHX2 BAIAP2 SCAF4

1.39e-031952634396_DN
DrugSTOCK1N-35874; Up 200; 14uM; PC3; HT_HG-U133A

KMT2B DBT RHOBTB2

1.39e-031952636583_UP
DrugSulfadoxine [2447-57-6]; Up 200; 12.8uM; MCF7; HT_HG-U133A

ZFHX2 RHOBTB2 SCAF4

1.39e-031952633547_UP
DrugLobelanidine hydrochloride [6112-86-3]; Down 200; 10.6uM; MCF7; HT_HG-U133A

ZFHX2 KMT2B SYNJ2

1.41e-031962632897_DN
DrugRiluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A

BAIAP2 CD2AP SCAF4

1.41e-031962634689_DN
DrugHesperidin [520-26-3]; Down 200; 6.6uM; HL60; HT_HG-U133A

SYNJ2 WIPF2 RHOBTB2

1.41e-031962631294_DN
DrugChlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; MCF7; HT_HG-U133A

BAIAP2 DBT SYNJ2

1.41e-031962635360_DN
DrugZuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A

KMT2B WIPF2 SOBP

1.41e-031962637356_DN
DrugHomatropine hydrobromide (R,S) [51-56-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A

BAIAP2 DBT SCAF4

1.41e-031962631684_UP
DrugRolitetracycline [751-97-3]; Down 200; 7.6uM; MCF7; HT_HG-U133A

BAIAP2 DBT SYNJ2

1.41e-031962635331_DN
DrugGSK-3beta Inhibitor VIII; Up 200; 10uM; MCF7; HT_HG-U133A

KMT2B SYNJ2 SCAF4

1.41e-031962637092_UP
Drug5162773; Down 200; 7uM; MCF7; HT_HG-U133A_EA

KMT2B SYNJ2 RHOBTB2

1.41e-03196263892_DN
DrugMethylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

BAIAP2 SYNJ2 SCAF4

1.41e-031962633183_DN
DrugPentoxifylline [6493-05-6]; Up 200; 14.4uM; MCF7; HT_HG-U133A

BAIAP2 SYNJ2 RHOBTB2

1.41e-031962636021_UP
Drugclozapine; Down 200; 10uM; PC3; HT_HG-U133A

ERF KMT2B SCAF4

1.41e-031962634453_DN
Drug2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A

BAIAP2 KMT2B SYNJ2

1.41e-031962635569_DN
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A

ZFHX2 SYNJ2 SOBP

1.41e-031962634580_DN
DrugPNU-0293363 [326823-19-2]; Up 200; 10uM; PC3; HT_HG-U133A

DBT SF3A1 RHOBTB2

1.41e-031962636568_UP
DrugDicloxacillin sodium salt [13412-64-1]; Down 200; 8.2uM; PC3; HT_HG-U133A

BAIAP2 KMT2B SOBP

1.41e-031962636666_DN
Drug(+/-)-blebbistatin; Down 200; 17uM; MCF7; HT_HG-U133A_EA

BAIAP2 SYNJ2 WIPF2

1.41e-03196263837_DN
DrugNortriptyline hydrochloride [894-71-3]; Down 200; 13.4uM; MCF7; HT_HG-U133A

KMT2B DBT SF3A1

1.41e-031962636003_DN
DrugD-cycloserine [68-41-7]; Down 200; 39.2uM; MCF7; HT_HG-U133A

BAIAP2 KMT2B SYNJ2

1.41e-031962636782_DN
Drug2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A

ZHX2 WIPF2 SOBP

1.41e-031962636934_UP
Drug2-propylpentanoic acid; Up 200; 500uM; MCF7; HT_HG-U133A_EA

BAIAP2 ERF SOBP

1.41e-031962631078_UP
DrugSulpiride [15676-16-1]; Down 200; 11.8uM; HL60; HG-U133A

ERF DBT WIPF2

1.41e-031962631967_DN
DrugMetyrapone [54-36-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A

BAIAP2 ERF SCAF4

1.41e-031962636447_DN
DrugTremorine dihydrochloride [300-68-5]; Down 200; 15uM; MCF7; HT_HG-U133A

DBT SOBP SCAF4

1.41e-031962636273_DN
Diseasehearing loss

MLXIPL SYNJ2

1.47e-0367252EFO_0004238
Diseasecholelithiasis

MLXIPL SYNJ2

2.52e-0388252EFO_0004799
Diseaseeosinophil percentage of leukocytes

MLXIPL KMT2B SF3A1 SPEF2

3.36e-03746254EFO_0007991
Diseasegallstones

MLXIPL SYNJ2

3.77e-03108252EFO_0004210
Diseasepathological myopia

DENND1A SOBP

3.98e-03111252EFO_0004207
Diseasewhite matter microstructure measurement

KMT2B RAPH1 SF3A1

4.25e-03390253EFO_0005674

Protein segments in the cluster

PeptideGeneStartEntry
LAPPPPPPQIKVEPI

ERF

416

P50548
KVVIKDPPPPPAPAP

ANTXR2

346

P58335
PVPPPPPIAKINGEV

CD2AP

416

Q9Y5K6
PTPPVPPAKKQPAFP

RAPH1

806

Q70E73
PVPVPVPVPVAPAVP

ATOH8

71

Q96SQ7
ILPPSPKVEIMPPPP

DBT

216

P11182
IPPPLPPKPKSIFIP

MAP4K3

431

Q8IVH8
TIPKPEPPPPVVPVK

KMT2B

246

Q9UMN6
VPPPVKQPPLPPTIS

KMT2B

2211

Q9UMN6
RAVPSPPPPPIVKKP

MYO15B

1021

Q96JP2
VQVPTLKKPLPPPPP

C3orf20

86

Q8ND61
GIVPPPPIPRPAKLQ

DENND1A

711

Q8TEH3
SPIPKPLPVPVPPIP

SCAF4

656

O95104
PLPPPPPAAQVAPIV

NUTM2F

156

A1L443
PLPPPPPAAQVAPIV

NUTM2G

156

Q5VZR2
IKVFPDPPPSIRPPP

SPEF2

1441

Q9C093
PPLEAPPLVPKVPPR

SYNJ2

1321

O15056
APFLPPKPPPPIIVV

RHOBTB2

231

Q9BYZ6
VQAVPPPPPVPTEPK

SF3A1

6

Q15459
VPPPLLHYPPPAKVP

MLXIPL

391

Q9NP71
IPGAKPLPVPPELAP

BAIAP2

271

Q9UQB8
QPVPTPVVLKPPLPP

C10orf55

116

Q5SWW7
PAPLFTPPVLPPFPL

ZFHX2

1336

Q9C0A1
IIVPLIPPPFIKPPA

SOBP

126

A7XYQ1
PYPVIVPLPVPIPIP

SOBP

526

A7XYQ1
PPAPPQPTPRKLVPI

SP2

56

Q02086
VPEPPPKVANPPLTP

ZHX2

426

Q9Y6X8
APPPVKPPPSPVNIR

WIPF2

226

Q8TF74